Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering
Details : XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 03, 2021
Details : Xenon has received a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), which recommends the granting of an orphan medicinal product designation for XEN496 for the treatment of KCNQ2-DEE.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 10, 2020
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 21, 2015
Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2013
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 28, 2013
Lead Product(s) : Ezogabine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 04, 2012
Lead Product(s) : Ezogabine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2012
Lead Product(s) : Ezogabine
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2012
Lead Product(s) : Ezogabine
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 24, 2012
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 30, 2012
Reset All
